Unit

UNIT 20.7 Identification of Human Tumor Antigens by Serological Analysis of Recombinant cDNA Expression Libraries (SEREX)

  1. Matthew J. Scanlan

Published Online: 1 MAR 2005

DOI: 10.1002/0471142735.im2007s65

Current Protocols in Immunology

Current Protocols in Immunology

How to Cite

Scanlan, M. J. 2005. Identification of Human Tumor Antigens by Serological Analysis of Recombinant cDNA Expression Libraries (SEREX). Current Protocols in Immunology. 65:20.7:20.7.1–20.7.19.

Author Information

  1. Memorial Sloan-Kettering Cancer Center, New York, New York

Publication History

  1. Published Online: 1 MAR 2005
  2. Published Print: FEB 2005

Abstract

The structural definition of human tumor antigens recognized by the autologous host has been a long-standing challenge in tumor immunology. The growing list of human tumor antigens recognized by autologous antibodies or cytotoxic T lymphocytes provides convincing evidence for immune recognition of cancer by the host of origin, as well as attractive targets for vaccine-based approaches to cancer therapy. In this regard, an approach called SEREX (serological analysis of recombinant cDNA expression libraries) has broad applicability to the analysis of the humoral immune response to cancer antigens. This method involves immunoscreening cDNA libraries prepared from tumor specimens with sera from cancer patients in order to identify gene products recognized by IgG antibody. Clones identified by SEREX can be directly sequenced, providing immediate structural definition of the antigenic target, and their expression profiles can be readily determined, providing information regarding their tissue distribution. Application of this technique has led to the discovery of a number of provocative tumor antigens.

Keywords:

  • SEREX;
  • Tumor Antigens;
  • Serum Antibody Detection Array (SADA);
  • Gene Discovery;
  • Immunotherapy;
  • Cancer Vaccines